Tonix Pharmaceuticals Holding Corp (TNXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has a cash flow conversion efficiency ratio of -0.162x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-39.65 Million) by net assets ($245.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Tonix Pharmaceuticals Holding Corp for the company's overall valuation and market capitalisation.
Tonix Pharmaceuticals Holding Corp - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Tonix Pharmaceuticals Holding Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tonix Pharmaceuticals Holding Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their cash flow conversion efficiency. See TNXP debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Core Molding Technologies Inc
NYSE MKT:CMT
|
0.032x |
|
Verkkokauppa.com Oyj
HE:VERK
|
-0.010x |
|
Sinar Mas Multiartha Tbk
JK:SMMA
|
0.075x |
|
Toro Ltd
LSE:TORO
|
-0.063x |
|
SCH Group Bhd
KLSE:0161
|
-0.097x |
|
JINSUNG T.E.C. Inc
KQ:036890
|
-0.016x |
|
Metsa Board Oyj A
HE:METSA
|
0.066x |
|
ÜSTRA Hannoversche Verkehrsbetriebe Aktiengesellschaft
F:HVB
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Tonix Pharmaceuticals Holding Corp (2008–2025)
The table below shows the annual cash flow conversion efficiency of Tonix Pharmaceuticals Holding Corp from 2008 to 2025. View Tonix Pharmaceuticals Holding Corp share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $245.15 Million | $-99.84 Million | -0.407x | +6.71% |
| 2024-12-31 | $139.56 Million | $-60.92 Million | -0.437x | +54.84% |
| 2023-12-31 | $105.53 Million | $-102.00 Million | -0.967x | -104.24% |
| 2022-12-31 | $207.18 Million | $-98.05 Million | -0.473x | -37.00% |
| 2021-12-31 | $218.72 Million | $-75.56 Million | -0.345x | +37.65% |
| 2020-12-31 | $87.65 Million | $-48.57 Million | -0.554x | +80.44% |
| 2019-12-31 | $9.42 Million | $-26.68 Million | -2.833x | -179.72% |
| 2018-12-31 | $23.66 Million | $-23.97 Million | -1.013x | -30.36% |
| 2017-12-31 | $24.62 Million | $-19.13 Million | -0.777x | +47.19% |
| 2016-12-31 | $25.36 Million | $-37.31 Million | -1.471x | -39.30% |
| 2015-12-31 | $40.26 Million | $-42.53 Million | -1.056x | -66.91% |
| 2014-12-31 | $36.09 Million | $-22.84 Million | -0.633x | +51.61% |
| 2013-12-31 | $6.51 Million | $-8.52 Million | -1.308x | +78.05% |
| 2012-12-31 | $958.71K | $-5.71 Million | -5.959x | -654.41% |
| 2011-12-31 | $-2.45 Million | $-2.64 Million | 1.075x | -66.04% |
| 2010-12-31 | $-5.68K | $-17.98K | 3.165x | +236.78% |
| 2009-12-31 | $12.04K | $-27.87K | -2.314x | -321.32% |
| 2008-12-31 | $42.91K | $-23.57K | -0.549x | -- |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more